{"id":"W2522519290","doi":"10.1016/j.ejca.2016.08.004","title":"Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Novartis Pharma; Exelixis; Canadian Centre for Applied Research in Cancer Control; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Everolimus; Medicine; Oncology; Renal cell carcinoma; Internal medicine; Urology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007589544,0.0002602713,0.0009310543,0.0004784543,0.00003467924,0.00002018192,0.0003263737,0.00002064502,0.0004025179],"category_scores_gemma":[0.00004152441,0.000140617,0.0002104361,0.0005371305,0.00008038631,0.0002027249,0.00005554113,0.000174751,0.00000559966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002616393,"about_ca_system_score_gemma":0.0002601056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005196891,"about_ca_topic_score_gemma":0.00003857105,"domain_scores_codex":[0.9973423,0.0004160065,0.001027695,0.000262337,0.000689359,0.0002623415],"domain_scores_gemma":[0.9977835,0.0001037641,0.001042944,0.0003637361,0.0004697081,0.0002362859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6211934,0.0103833,0.2858931,0.0001131474,0.003870755,0.002483806,0.0006654763,0.000339579,0.005481502,0.000002002121,0.001197838,0.0683761],"study_design_scores_gemma":[0.6920449,0.03365663,0.2588511,0.0003846368,0.003458039,0.00001778718,0.00002285479,0.00003822896,0.009342661,0.000004979353,0.001926923,0.0002512972],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959416,0.001819879,0.0004559553,0.0004467193,0.0001235774,0.0006069699,0.00005105316,0.000003763983,0.0005504806],"genre_scores_gemma":[0.9974429,0.0004021578,0.001209731,0.0001079782,0.0001932909,0.000008182871,0.000007969057,0.0000512576,0.0005765083],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07085153,"threshold_uncertainty_score":0.5734195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05198801059173726,"score_gpt":0.3128697897938985,"score_spread":0.2608817792021612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}